BiotechTube

VN-0200

Phase 2Completed
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Respiratory Syncytial Virus Infections

Conditions

Respiratory Syncytial Virus Infections

Trial Timeline

Oct 13, 2022 → Feb 15, 2024

NCT ID
NCT05547087

About VN-0200

VN-0200 is a phase 2 stage product being developed by Daiichi Sankyo for Respiratory Syncytial Virus Infections. The current trial status is completed. This product is registered under clinical trial identifier NCT05547087. Target conditions include Respiratory Syncytial Virus Infections.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT05547087Phase 2Completed

Competing Products

20 competing products in Respiratory Syncytial Virus Infections

See all competitors
ProductCompanyStageHype Score
Zopapogene imadenovec (Zopa)PrecigenApproved
80
PRGN-2012 - Phase I; Dose Level 1 + PRGN-2012 - Phase I; Dose Level 2 + PRGN-2012 - Phase II; Dose Level 2PrecigenPhase 1/2
36
agenT-797MiNK TherapeuticsPhase 1
25
YMC026 + PlaceboYuhanApproved
85
VN-0200 + PlaceboDaiichi SankyoPhase 1
33
Isavuconazonium Injection [Cresemba] + PlaceboAstellas PharmaPhase 3
77
S-337395 + PlaceboShionogiPhase 2
52
SivelestatEli LillyPhase 1/2
41
Itolizumab IV infusion + Best supportive care (BSC)BioconPhase 2
52
Paracetamol 500 mg/Phenylephrine 5 mg tablets + Paracetamol 1000 mg/Phenylephrine 10 mg sachetJohnson & JohnsonPhase 1
33
Mesenchymal stem cellRohto PharmaceuticalPhase 1
33
PalivizumabAbbViePhase 3
77
PalivizumabAbbViePhase 3
77
Placebo + AZD5634AstraZenecaPhase 1
33
MEDI8897 + PalivizumabAstraZenecaPhase 2/3
65
Selumetinib + DurvalumabAstraZenecaPhase 2
52
Tozorakimab + PlaceboAstraZenecaPhase 3
77
NirsevimabAstraZenecaPhase 3
77
Nirsevimab + PlaceboAstraZenecaPhase 3
77
MEDI8897 + PlaceboAstraZenecaPhase 3
77

Other Products from Daiichi Sankyo

Olmesartan medoxomil + Olmesartan medoxomil/hydrochlorothiazide + HydrochlorothiazideApproved
85
OAC aloneApproved
85
olmesartan medoxomil + Placebo + losartan potassiumApproved
85
Prasugrel + ClopidogrelApproved
85
Diet+pravastatinApproved
85